CEMP Cempra Inc

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Cempra, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Cempra, Inc. securities (NASDAQ:CEMP) from May 1, 2016 through November 1, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Cempra investors under the federal securities laws.

To join the Cempra class action, go to http://www.rosenlegal.com/cases-985.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) one of Cempra’s lead product candidate, solithromycin, posed significant safety risks for hepatotoxicity; and (2) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-985.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

EN
11/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cempra Inc

 PRESS RELEASE

Melinta Therapeutics Announces Appointment of Christine Ann Miller as ...

Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer MORRISTOWN, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020. In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Compan...

GlobalData Department
  • GlobalData Department

Cempra Inc (CEMP) - Pharmaceuticals & Healthcare - Deals and Alliances...

Summary Cempra Inc (Cempra), formerly Cempra Holdings LLC is a pharmaceutical company that develops antibacterials to the critical medical needs. The company offers products which include solithromycin and fusidic acid. It offers solithromycin, an oral and intravenous fluoroketolide. Cempra offers fusidic acid which is active against gram-positive organisms including MRSA. The company offers macrolides which are antimicrobial drugs that are active against aerobic and anaerobic gram-positive coc...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Cempra, ...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Cempra, Inc. (NASDAQ:CEMP) between October 22, 2015 and November 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Middle District of North Carolina. To get more information go to: http://www.zlk.com/pslra/cempra-inc or contact Joseph E. Levi, Esq. either via email at jlev...

 PRESS RELEASE

GPM Reminds Investors of the January 3 Deadline in the Class Action La...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 3, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Cempra, Inc. (“Cempra” or the “Company”) (NASDAQ: CEMP) securities between May 1, 2016 and November 1, 2016, inclusive (the “Class Period”). Cempra investors have until January 3, 2017 to file a lead plaintiff motion. The Complaint filed in this lawsuit alleges that throughout the Class Period, Defendant...

 PRESS RELEASE

CEMP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareh...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Middle District of North Carolina on behalf of investors who purchased Cempra, Inc. (NASDAQ:CEMP) securities between October 22, 2015 and November 1, 2016. Click here to learn about the case: http://www.wongesq.com/pslra/cempra. There is no cost or obligation to you. According to the complaint, during the Class Period, Cempra made false and/or misleading statements and/or failed to d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch